Sleep disorders related to HIV treatment
e202306052
Keywords:
Insomnia, HIV, Dolutegravir, Bictegravir, Adverse drug reactions, Quality of lifeAbstract
BACKGROUND // HIV Clinical Guidelines have positioned integrase inhibitors recently as first-line treatment. However, two of these drugs have also been associated with adverse side effects on the central nervous system, especially with sleep disturbances. The objective was to analyse the influence of bictegravir and dolutegravir on the sleep quality in HIV patients.
METHODS // An observational, cross-sectional study was carried out between December 2020 and January 2021 in HIV patients attended in a pharmacy care clinic. Demographic and adherence variables were collected. Sleep quality was measured using the Pittsburgh questionnaire or PSQI. We classified patients into two groups: patients with bictegravir or dolutegravir in their treatment (study group) and the rest (control group). The influence of the variables collected on the PSQI result was analysed using the Chi-Square test for categorical variables and the student t-test or Mann-Whitney U test for continuous variables.
RESULTS // One hundred and nineteen patients were included. 64% in the study group and 67% in the control group suffered from sleep disorders according to the PSQI questionnaire (p=0.788). Neither were statistical differences found when the different components of sleep were analysed between the two groups.
CONCLUSIONS // A high percentage of patients, regardless of whether their treatment includes bictegravir or dolutegravir, have problems with their sleep quality. We didn’t find a correlation between sleep quality and treatment with bictegravir or dolutegravir compared to the other treatments.
Downloads
References
Portilla-Tamarit J, Reus S, Portilla I, Fuster Ruiz-de-Apodaca MJ, Portilla J. Impact of Advanced HIV Disease on Quality of Life and Mortality in the Era of Combined Antiretroviral Treatment. J Clin Med. 2021;10(4):716.
Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP, Klein DB et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J Acquir Immune Defic Syndr. 2016;73(1):39-46.
Bourgi K, Wanjalla C, Koethe JR. Inflammation and Metabolic Complications in HIV. Curr HIV/AIDS Rep. 2018;15(5):371-381.
Johnston PI, Wright SW, Orr M, Pearce FA, Stevens JW, Hubbard RB et al. Worldwide relative smoking prevalence among people living with and without HIV: a systematic review and meta-analysis. AIDS. 2021;35(6):957-970.
Dalwadi DA, Ozuna L, Harvey BH, Viljoen M, Schetz JA. Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs. Pharmacol Rev. 2018;70(3):684-711.
Taibi DM. Sleep Disturbances in Persons Living with HIV. J Assoc Nurses AIDS Care. 2013;24(1 Suppl):S72-85.
Hoffmann C, Llibre JM. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors. AIDS Rev. 2019;21(1):4-10.
Bugueño M, Curihual C, Olivares P, Wallace J, López-AlegrÍa F, Rivera-López G et al. [Quality of sleep and academic performance in high school students]. Rev Med Chil. 2017;145(9):1106-1114.
Murrell DE, Cluck DB, Moorman JP, Brown SD, Wang K-S, Duffourc MM et al. HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study. Clin Drug Investig. 2019;39(3):285-299.
Morillo-Verdugo R, Polo R, Knobel H. [Consensus document on enhancing medication adherence in patients with the human immunodeficiency virus receiving antiretroviral therapy]. Farm Hosp. 2020;44(4):163-173.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Manuel Vélez-Díaz-Pallarés, Beatriz Esteban-Cartelle, Teresa Gramage-Caro, Beatriz Montero-Llorente, María de los Ángeles Parro-Martín, Miguel Ángel Rodríguez-Sagrado, Ana María Álvarez-Díaz
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
